- Company
- Samsung Bioepis’ 3mth operating profit exceeds last year's
- by Chon, Seung-Hyun Jul 26, 2024 05:47am
- Samsung Bioepis posted the largest Q2 revenue in its history. The company recorded twice as much revenue as in its previous record, and its operating income surpassed what it earned in the entire year last year. This is due to the large influx of milestones, receiving a series of approvals for biosimilars in the U.S. and Europe. According to
- Company
- "Active viral hepatitis treatment can prevent carcinoma"
- by Son, Hyung-Min Jul 26, 2024 05:47am
- "Most individuals affected by viral hepatitis do not have symptoms. They may not be aware of their infection. When individuals realize that they have abnormalities in their body, liver disease has already progressed. It is important to identify and treat patients early in their disease progression to prevent complications related to hepato
- Company
- Mitsubishi accepts DREC results for Uplizna...nears reimb
- by Eo, Yun-Ho Jul 26, 2024 05:47am
- Mitsubishi Tanabe Pharma’s twice-yearly neuromyelitis optica spectrum disorder (NMOSD) drug Uplizna is headed for reimbursement listing in Korea. According to industry sources, Mitsubishi Tanabe Pharma’s Korea accepted the ‘below the evaluated amount’ condition set by the Health Insurance Review and Assessment Service's Drug Reimburse
- Company
- Guidelines for new obesity drugs must be established
- by Moon, sung-ho Jul 26, 2024 05:46am
- Obesity is projected to impact around 2 billion individuals by 2035. Including overweight, about 4 billion individuals will be affected by obesity, making it a significant global healthcare issue. Following this trend, pharmaceutical and biotech industry is focusing on developing next-generation treatments for obesity. Glucagon-like peptid
- Company
- Antibiotic prescriptions had surged with the pandemic
- by Kim, Jin-Gu Jul 25, 2024 05:51am
- The amount of outpatient antibiotic prescriptions in Korea had changed dramatically during the COVID-19 pandemic. In 2020 and 2021, early stages of the pandemic, antibiotic prescriptions dropped sharply but then surged in 2022. In contrast, the proportion of cephalosporin and quinolone antibiotic prescriptions, which are more powerful than ot
- Company
- Meningitis B vaccine Bexsero is released in Korea
- by Moon, sung-ho Jul 25, 2024 05:51am
- Competition in the 'meningococcal' vaccine market, which is mainly vaccinated in pediatric clinics, has recently been reignited. Although its domestic market is worth less than KRW 10 billion, the emergence of next-generation vaccines is expected to spark new competition among multinational pharmaceutical companies. This is because GSK
- Company
- 'Padcev+Keytruda' combination therapy is set to land in KOR
- by Eo, Yun-Ho Jul 25, 2024 05:51am
- The combination therapy of 'Padcev+Keytruda,' which is expected to bring a paradigm shift to bladder cancer treatment, will soon land in South Korea. The Ministry of Food and Drug Safety (MFDS) is reviewing the expansion of indication for Astellas Korea's Padcev (enfortumab), an antibody-drug conjugate (ADC), in combination with Keytruda
- Company
- Samsung Bioepis’ Soliris biosimilar is approved in the U.S.
- by Chon, Seung-Hyun Jul 24, 2024 05:51am
- [데일리팜=천승현 기자] 삼성바이오에피스는 미국 식품의약품국(FDA)으로부터 희귀질환치료제 ‘에피스클리’의 품목허가를 획득했다고 23일 밝혔다. 에피스클리는 미국 알렉시온이 개발한 솔리리스의 바이오시밀러 제품이다. 에피스클리는 발작성 야간 혈색소뇨증, 비정형 용혈성 요독 증후군의 치료제로 FDA 승인을 받았다. 삼성바이오에피스는 2019년 7월부
- Company
- Reimb applied for new HIV drug 'Vocabria+Rekambys'
- by Eo, Yun-Ho Jul 24, 2024 05:50am
- Long-acting HIV treatment 'Vocabria+Rekambys' combination therapy aims to be listed for insurance reimbursement after receiving approval in South Korea two years ago. Industry sources said that GSK Korea and Janssen Korea have applied for reimbursement for the combination therapy of Vocabria (cabotegravir) and Rekambys (rilpivirine), whic
- Company
- Will 'Zejula' be reimbursed for HRD-positive ovarian cancer?
- by Eo, Yun-Ho Jul 23, 2024 05:48am
- Whether the insurance reimbursement criteria for 'Zejula,' a PARP inhibitor, will include 'HRD-positive' is gaining attention. Sources said that Takeda Pharmaceuticals Korea is negotiating the price with the National Health Insurance Service (NHIS) for the Poly ADP-ribose Polymerase (PARP) inhibitor, Zejula, which is used to treat ovarian
